Business Context and Reporting Period
This Form 8-K, filed on May 19, 2014, reports on an event occurring on May 16, 2014. The registrant is Ventrus Biosciences, Inc. (Ventrus), which entered into an Agreement and Plan of Merger with Assembly Pharmaceuticals, Inc. (Assembly). Under the agreement, a wholly-owned subsidiary of Ventrus will merge with Assembly, resulting in Assembly becoming a wholly-owned subsidiary of Ventrus.
Key Financial Metrics and Transaction Terms
This filing describes a merger transaction rather than a standard financial reporting period. Consequently, it does not contain revenue, profit, cash flow, or margin data for either company. Key financial terms of the transaction include:
- Merger Consideration: Assembly shareholders will receive Ventrus common stock based on an exchange ratio. The total number of Ventrus shares to be issued is fixed at 23,152,500.
- Exchange Ratio Calculation: The ratio is the quotient of 23,152,500 divided by the total number of Assembly shares outstanding (including those issuable upon conversion of convertible promissory notes) at the closing date.
- Convertible Notes: All outstanding Assembly convertible promissory notes must be converted into Assembly common stock prior to the effective time of the Merger.
- Liquidity Condition: A condition to Assembly's obligation to consummate the Merger is that Ventrus must have "Cash" of at least $20,000,000 at closing.
- Termination Fee: If the Merger Agreement is terminated due to a lack of Ventrus stockholder approval, Ventrus has agreed to pay up to $250,000 of Assembly's reasonable legal fees and expenses.
Material Changes and Transaction Structure
The primary material change is the proposed acquisition of Assembly by Ventrus. The transaction structure involves:
- Equity Awards: Assembly restricted stock will become fully vested and convert into Merger Consideration. Unexercised Assembly stock options will convert into options to purchase Ventrus common stock.
- Appraisal Rights: Dissenting Assembly shareholders may exercise appraisal rights under Delaware law to receive a judicially determined cash amount per share instead of the Merger Consideration.
- Board Composition: Ventrus is required to restructure its board of directors and officers to include certain persons designated in the agreement.
- Insurance: Ventrus must purchase a representation and warranty (R&W) insurance policy, with the premium added to the required closing cash balance.
Guidance, Outlook, Risks, and Contingencies
The filing contains no financial guidance or outlook for future operating results. It outlines significant risks and contingencies regarding the completion of the Merger:
- Closing Conditions: The Merger is subject to customary conditions, including stockholder approval by both Ventrus and Assembly, NASDAQ listing maintenance, and the absence of a "Material Adverse Effect" on either party.
- Dissenting Shares Limit: The Merger cannot close if more than 5% of Assembly's issued and outstanding shares (including restricted stock) become Dissenting Shares.
- Termination Rights: Either party may terminate the agreement if the Merger is not consummated by August 15, 2014 (subject to extensions), if a legal prohibition arises, or if a material breach occurs. Termination is also permitted if a party's board recommends an alternate transaction involving the sale of more than 10% of assets or capital stock.
- Forward-Looking Statements: The filing warns that actual results may differ due to risks including failure to satisfy conditions, legal proceedings, operational disruptions, and employee retention issues.
Important Facts for Investor Verification
- Verify the final exchange ratio once the total number of Assembly shares outstanding (including converted notes) is determined at closing.
- Confirm whether Ventrus maintains the required $20,000,000 cash balance at closing, inclusive of the R&W insurance premium.
- Monitor the percentage of Dissenting Shares to ensure it remains below the 5% threshold required for closing.
- Review the upcoming definitive proxy statement for detailed information on the transaction, board recommendations, and voting procedures.
- Note the August 15, 2014 "End Date" by which the Merger must be consummated unless extended.